NASDAQ$AQST
Aquestive Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a progress update on the key 2023 objectives.
Aquestive Therapeutics reported a decrease in total revenues for Q4 2022, with a net loss of $12.4 million, but showed progress in financial turnaround actions including debt reduction and securing non-dilutive capital. The company is focused on advancing AQST-109, working with the FDA for Libervant, expanding manufacturing capabilities, and strengthening its balance sheet.
- Pivotal study for AQST-109 (epinephrine sublingual film) on track to start in third quarter 2023.
- Financial turnaround actions on track including 18% reduction of outstanding debt and the receipt of $20 million of non-dilutive capital in the first quarter of 2023.
- Continues to engage FDA on next steps for Libervant™ (diazepam) Buccal Film.
- Provides full year 2023 financial outlook.
Headline financials
Revenue & EPS history
Aquestive · Revenue · Quarterly
$10.7M
Forward guidance
Aquestive is providing its full year 2023 financial outlook. The Company expects:
Tailwinds
- Total revenue (in millions)$37 to $41
- GuidanceTotal revenue (in millions)$37 to $41
- Non-GAAP adjusted EBITDA loss (in millions)$31 to $36
- manufacturing and supply revenue and royalty fees
- includes continued focused R&D investments related to the development of AQST-109.
Headwinds
- revenue guidance for 2023 no longer includes proprietary net sales for Sympazan due to the license of Sympazan to Assertio
- but it does include manufacturing and supply revenue and royalty fees.
- In addition, the guidance for 2023 includes continued focused R&D investments related to the development of AQST-109.
- Please note the Company's revenue guidance for 2023 no longer includes proprietary net sales for Sympazan due to the license of Sympazan to Assertio
- In addition, the guidance for 2023 includes continued focused R&D investments related to the development of AQST-109.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-0.4%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+8.5%
Avg return
30 days after
45%
14 / 31 earnings
Positive
+22.8%
Q3 2019
Best reaction
-44.2%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.2% | -1.0% | +0.0% | |
| Q4 2025 | -2.5% | -3.9% | -5.5% | |
| Q3 2025 | +2.0% | -5.2% | +6.3% | |
| Q1 2025 | -19.4% | -16.5% | +16.1% | |
| Q4 2024 | -7.5% | -5.4% | -2.9% | |
| Q3 2024 | -13.8% | -1.1% | -21.9% | |
| Q2 2024 | +4.3% | +4.3% | +28.6% | |
| Q1 2024 | -11.7% | -11.7% | -19.7% | |
| Q4 2023 | +20.3% | +16.7% | -0.5% | |
| Q3 2023 | +6.9% | +5.0% | +28.7% | |
| Q2 2023 | -7.2% | -7.2% | -24.4% | |
| Q1 2023 | +20.9% | +46.8% | +66.2% | |
| Q4 2022 | +5.6% | -1.4% | +45.3% | |
| Q3 2022 | -3.4% | +0.6% | +7.5% | |
| Q2 2022 | -2.2% | +2.7% | +50.5% | |
| Q1 2022 | +0.7% | -14.2% | -32.6% | |
| Q4 2021 | -4.8% | -12.6% | -18.0% | |
| Q3 2021 | +12.6% | +10.7% | +2.7% | |
| Q2 2021 | +11.2% | +12.1% | +39.6% | |
| Q1 2021 | -3.3% | -14.1% | -6.8% | |
| Q4 2020 | +11.5% | +24.6% | +11.5% | |
| Q3 2020 | +3.6% | +4.9% | +29.6% | |
| Q2 2020 | +4.0% | +10.5% | +26.5% | |
| Q1 2020 | -4.0% | +14.4% | +14.2% | |
| Q4 2019 | -44.2% | -55.2% | -16.0% | |
| Q3 2019 | +22.8% | +26.8% | +95.8% | |
| Q2 2019 | +12.5% | +22.7% | +14.1% | |
| Q1 2019 | -11.4% | -14.9% | -29.9% | |
| Q4 2018 | -14.4% | -8.3% | -18.7% | |
| Q3 2018 | -1.1% | -7.8% | -15.1% | |
| Q2 2018 | -0.3% | +5.3% | -7.7% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro